GlaxoSmithKline, a London-based drug giant is partnering with 23andMe, the San Francisco genetics startup, to develop new medicines. The companies will split costs and profits equally, and Glaxo will make a $300 million investment in 23andMe. The collaboration will last four years.
23andMe Gets $300 Million Boost From GlaxoSmithKline To Develop New Drugs
